Your browser doesn't support javascript.
SARS-CoV-2 epidemiological trend before vaccination era: a seroprevalence study in Apulia, Southern Italy, in 2020.
Marchi, Serena; Coppola, Chiara; Piu, Pietro; Benincasa, Linda; Dapporto, Francesca; Manenti, Alessandro; Viviani, Simonetta; Montomoli, Emanuele; Trombetta, Claudia Maria.
  • Marchi S; Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy.
  • Coppola C; Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy.
  • Piu P; VisMederi srl, 53100 Siena, Italy.
  • Benincasa L; VisMederi Research srl, 53100 Siena, Italy.
  • Dapporto F; VisMederi srl, 53100 Siena, Italy.
  • Manenti A; VisMederi srl, 53100 Siena, Italy.
  • Viviani S; Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy.
  • Montomoli E; Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy.
  • Trombetta CM; VisMederi srl, 53100 Siena, Italy.
Z Gesundh Wiss ; : 1-6, 2023 Feb 04.
Article in English | MEDLINE | ID: covidwho-2232974
ABSTRACT

Aim:

The present study aimed at assessing the prevalence of antibodies against SARS-CoV-2 in the general population in the province of Bari (Apulia region, Southern Italy) during the year 2020. Subject and

methods:

In this study, 1325 serum samples collected from January to December 2020 were tested for the presence of IgM and IgG antibodies against whole-virus SARS-CoV-2 antigen by commercial ELISA. Positive samples were further tested by in-house ELISA for the detection of anti-receptor binding domain (RBD) IgM and IgG antibodies and by micro-neutralization (MN) assay for the detection of neutralizing antibody.

Results:

One hundred (7.55%) samples had the presence of at least one antibody class against SARS-CoV-2 by commercial ELISA, of which 88 (6.6%) showed IgG and 19 (1.4%) showed IgM antibodies. The proportion of samples with IgG antibodies increased from 1.9% in January-February to 9.6% in November-December, while no significant increase was observed for IgM. When tested by in-house ELISA and MN assay, 17.0% and 31.6% were found positive to RBD IgG and RBD IgM, respectively, while 12.0% showed neutralizing antibody.

Conclusion:

The proportion of samples with SARS-CoV-2 IgG antibodies increased during 2020, especially in the second half of the year, consistent with data reported by the routine epidemiological surveillance of SARS-CoV-2 cases. Despite the high number of reported cases, the seroprevalence values are relatively low, and only a small proportion of samples had neutralizing antibodies. Supplementary Information The online version contains supplementary material available at 10.1007/s10389-023-01834-3.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study Topics: Vaccines Language: English Journal: Z Gesundh Wiss Year: 2023 Document Type: Article Affiliation country: S10389-023-01834-3

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study Topics: Vaccines Language: English Journal: Z Gesundh Wiss Year: 2023 Document Type: Article Affiliation country: S10389-023-01834-3